NGS/Metabolomic Approaches in Stratification of Resistant Hypertension
Research type
Research Study
Full title
Next Generation Sequencing and Metabolomic Approaches in Stratification of Resistant Hypertension
IRAS ID
154423
Contact name
Sandosh Padmanabhan
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Hypertension (high blood pressure) is becoming increasingly common and is the leading risk factor for the development of stroke and heart disease. Drug therapy is the mainstay of treatment for hypertension and there are five classes of drugs used as the first-line agents and many other second-line agents. Currently the choice of initial drug(s) is based upon patient’s age and ethnic background. Despite the availability of numerous drugs, response rates to any given drug are approximately 50% and only 1/3 patients with hypertension have their blood pressure controlled to target.
We will characterise the responder/non-responder status of 2000 patients who attend the Glasgow Blood Pressure Clinic to different antihypertensive drugs. Through rigorous review of longitudinal BP measurements and prescription data, we will attribute response status for multiple drugs to each patient. This is the unique aspect of our study, as our protocol reflects real-life patient profiles.
We aim to perform detailed global analysis of DNA and biochemical profiles using next generation sequencing (NGS, genetic testing) and metabolomics studies respectively. NGS is targeted sequencing of a selected set of genes – in contrast to whole genome or exome sequencing. This provides complete coverage of the genes of interest. For this study we require one sample of blood (5 mls) from each patient. NHS Scotland has already developed a NGS panel, list of hypertension genes developed by Aberdeen clinical genetics, which we shall use for genetic screening and the metabolomic analysis will be performed in the Glasgow Polyomics Facility. We seek to identify genetic or metabolomics markers associated with response or non-response to different antihypertensive drugs in our rigorously selected patients and these results will be used to inform a larger trial studying if markers can be used to guide treatment.
Metabolomics sample will be stored, analysis will depend on on securing additional funding.
REC name
London - Bromley Research Ethics Committee
REC reference
14/LO/1887
Date of REC Opinion
27 Oct 2014
REC opinion
Further Information Favourable Opinion